Skip to main content
| News

Novartis subsidiary Alcon is now an independent company

09.04.2019

Novartis completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution. The Basel pharma giant reports it is now positioned for sustained growth and announced the launch of potential blockbusters.

Basel bridge Novartis Campus Rhine River Innovation Business

The successful execution of the spin-off of Alcon allows Novartis to now fully focus on its medicines, the Basel pharma company reported in a press release. This will also lead to higher group margins. In particular, it plans to improve the Innovative Medicines divisions, in which Novartis is aiming for core margins into the mid-30s by 2022. After granting shareholders a dividend of 2.85 Swiss francs per share for 2019, it plans to pay a “strong and growing annual dividend” in future. The share buyback of up to US$ 5 billion announced in June 2018 is expected to be completed this year.

For achieving sustained growth going forward, Novartis is looking to launch ten potential blockbusters in the next two years.  A blockbuster is a drug with annual sales of at least US$ 1 billion. The company also has an additional 20 potential blockbusters on the horizon.

Shares in the spin-off eye specialist Alcon are now listed on the SIX Swiss Exchange and on the New York Stock Exchange. The company was valued at around US$ 27 billion on flotation. “This is an incredibly exciting day for both Novartis and Alcon,” said CEO Vas Narasimhan in the Novartis press release. Alcon has achieved continuous growth and gone public from a position of great strength. “At Novartis, we continue to reimagine ourselves as a leading medicines company powered by breakthrough medicines, data science and advanced therapy platforms.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area achieves milestone with settling of LifeMine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel Area achieves milestone with settling of LifeMine

Life sciences company LifeMine Therapeutics from the USA has established its European headquarters in the Basel Area. With this, Basel...

Read More
Space Pharmaceuticals establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Space Pharmaceuticals establishes presence in Basel

Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...

Read More
Basel Area Business & Innovation, Innovation, Life Sciences / biotech

NextImmune to benefit from Venture Kick financing

The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...

Read More
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

OECD impressed by the canton of Jura’s innovation system

The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest

ti&m opens branch in Basel

ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...

Read More
What can artificial intelligence do for health?
Basel Area Business & Innovation, Digital Health, Innovation, Life Sciences / biotech, Medtech

What can artificial intelligence do for health?

Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Economic promotion agency creates 55 new jobs in Jura

The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...

Read More
Investors top up capital of BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors top up capital of BioVersys

BioVersys has raised 24.2 million Swiss francs in a series C funding round. The Basel-based pharmaceutical company plans to use...

Read More
Basel Area Business & Innovation, ICT, Innovation

Swiss made software label awarded to 1000th company

Swiss made software GmbH has now awarded its seal of quality to its 1,000th member firm. The “swiss made software”...

Read More
EvokAI to acquire Advancience
Basel Area Business & Innovation, Digital Health, Innovation, Invest, Medtech

EvokAI to acquire Advancience

EvokAI Creative Labs Inc. has agreed a deal to acquire Advancience. The diagnosis profiles enhanced by Artificial Intelligence (AI) developed...

Read More
1 2 3 34

Do you have a question? We'd like to hear from you.